Company: JUNS
Filing Date: 2025-11-06
Form Type: DEF 14A
Source: 0001493152-25-020988
Chunk: 18

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-06
Form: DEF 14A
Chunk 18
---
 and Director                |
| Alison         
 D. Silva       |     |  47 |     | President,                                     
 Chief Business Officer, and Director           |
| Nicholas       
 H. Hemmerly    |     |  43 |     | Independent                                    
 Director                                       |
| Julie          
 Kampf          |     |  64 |     | Independent                                    
 Director                                       |
| Allison        
 W. Brady       |     |  54 |     | Independent                                    
 Director                                       |
| Holger         
 Weis           |     |  62 |     | Independent                                    
 Director                                       |

Executive Officers

Christer Rosén.Mr. Rosén is our Co-Founder and has served as our Chief Executive Officer and Chairman of our Board of Directors since January 1, 2016. From 1997 through May 2015, Mr. Rosén founded and served as the Chief Executive Officer and Chairman of EffRx Pharmaceuticals. Mr. Rosén together with Marshall Hayward, our Chief Scientific Officer, held the same position at EffRx, invented, developed and received FDA and EU approvals of a drug treating osteoporosis, Binosto ®. Binosto ®is distributed in several parts of the world and gave Mr. Rosén a full insight in all the aspects of pharmaceutical development, regulatory paths and distribution. Mr. Rosén is a graduate of Malmo Trade Schools/Lund University, Sweden, with a degree in Computer Sciences in 1971. Mr. Rosén is well-qualified to serve as a director given his proven leadership in founding and leading pharmaceutical companies and successfully bringing FDA- and EU-approved drugs to market.

Marshall Hayward, Ph.D.Dr. Hayward is one of our Co-Founders, serves as our Chief Scientific Officer, and is a member of our Board of Directors since January 1, 2016. Since May 2013, Dr. Hayward has served as the managing member of Marshall Hayward Associates LLC. From September 2003 to May 2013, Dr. Hayward served as the Chief Scientific Officer of EffRx Pharmaceuticals where he was instrumental in all aspects of the development and approvals of the Binosto® product. Dr. Hayward received a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign in 1982 and did postdoctoral work there in molecular biology. Dr. Hayward received a B.S. degree (in Biochemistry with High Honor) from the Honors College of Michigan State University in 1977. Dr. Hayward does not hold, and has not